Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: Efficacy
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: Efficacy
复制标题
DOI：
10.1016/j.amjcard.2007.10.010
复制
发表时间：
2007-12-17
影响因子：
2.8
通讯作者：
Isoldi, Kathy Keenan
中科院分区：
文献类型：
--
作者：
Aronne, Louis J.;Isoldi, Kathy Keenan
腹内脂肪量或中心性肥胖与心血管风险密切相关。脂肪组织是一种内分泌器官，能分泌影响食欲、能量代谢和动脉粥样硬化的激素和细胞因子。美国国家心肺血液研究所(NHLBI)指南建议，如果饮食和生活方式干预措施不能对体重指数为27和与体重相关的合并症以及体重指数为30的患者产生良好结果，治疗计划可能包括减肥药物。近年来，内源性大麻素系统已成为肥胖和心脏代谢危险因素药物治疗的有效靶点。本文对选择性大麻素1受体利莫那班的临床试验结果进行了深入的综述。(最近，FDA咨询委员会建议推迟批准利莫那班，因为安全问题需要在进一步的研究中解决。)与安慰剂相比，利莫那班20毫克显著降低了体重和腰围。此外，利莫那班与其他几种心脏代谢风险因素的有利变化有关，包括血清高密度脂蛋白胆固醇和脂联素水平的显著上升，以及血清甘油三酯、小而致密的低密度脂蛋白颗粒、C反应蛋白、胰岛素抵抗和糖化血红蛋白水平的降低。(C)2007 Elsevier Inc.保留所有权利。
Intra-abdominal fat mass, or central adiposity, and cardiovascular risk are strongly correlated. Adipose tissue is an endocrine organ that secretes hormones and cytokines influencing appetite, energy metabolism, and atherosclerosis. National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend that if dietary and lifestyle interventions fail to produce favorable outcomes in individuals with a body mass index >27 and weight-related comorbidities, as well as those with a body mass index >30, treatment plans may include weight loss medication. The endocannabinoid system has recently emerged as a viable target for the pharmacologic treatment of obesity and cardiometabolic risk factors., This article provides an in-depth review of efficacy results from clinical trials of rimonabant, a selective cannabinoid-1 receptor. (Recently, an FDA Advisory Committee recommended a delay in the approval of rimonabant because of safety issues that need to be addressed in further studies.) Compared with placebo, rimonabant 20 mg significantly decreased body weight and waist circumference measurements. In addition, rimonabant was associated with favorable changes in several other cardiometabolic risk factors, including significant increases in serum levels of high-density lipoprotein cholesterol and adiponectin, as well as reductions in serum levels of triglycerides, small, dense low-density lipoprotein particles, C-reactive protein, insulin resistance, and glycosylated hemoglobin. (c) 2007 Elsevier Inc. All rights reserved.